Glatiramer Acetate Injection, Solution
Product Images NDC 82983-430

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Glatiramer Acetate (NDC 82983-430). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ajenat Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure B (Fig B)

An instructional illustration showing hands preparing a pre-filled syringe for subcutaneous injection. One hand holds the syringe packaging, while the other hand is removing the syringe from the packaging, demonstrating proper handling technique.*

FDA Label Image

Figure C (Fig C)

An instructional diagram showing four sections of the body recommended for subcutaneous injections. It highlights injection areas on the abdomen (excluding about 2 inches around the belly button), back of the hips and arms (fleshy areas of the upper hips below the waist and upper back portion of the arms), front of the arms (fleshy areas of the upper back portion), and thighs (about 2 inches above the knee and 2 inches below the groin). Each area is shaded to indicate preferred injection sites.*

FDA Label Image

Figure D (Fig D)

Illustration showing a person pinching the skin, presumably to prepare for a subcutaneous injection. The image highlights the technique of lifting the skin fold with fingers, often used for administering subcutaneous injections like Glatiramer Acetate solution.*

FDA Label Image

Figure E1 (Fig E1)

An instructional line drawing depicting a hand holding a syringe at an angle, likely demonstrating the proper grip or technique for administering a subcutaneous injection.*

FDA Label Image

Figure E2 (Fig E2)

Illustration showing hands holding a syringe and a needle cap, depicting the process of attaching or preparing the injection needle for subcutaneous administration.*

FDA Label Image

Figure E3 (Fig E3)

An illustration showing a hand holding a syringe poised to perform a subcutaneous injection, with a small rectangular object nearby on a flat surface. The image likely demonstrates the injection technique related to glatiramer acetate 40 mg/mL subcutaneous injection.*

FDA Label Image

Figure F (Fig F)

An instructional illustration showing a hand pinching the skin, typically demonstrating how to prepare or administer a subcutaneous injection.*

FDA Label Image

Figure G (Fig G)

An instructional illustration showing a hand holding a syringe injecting a solution subcutaneously into the forearm. This demonstrates the subcutaneous injection technique commonly used for administering certain medications.*

FDA Label Image

Figure H (Fig H)

An instructional line drawing showing a person administering a subcutaneous injection into the thigh with a syringe. The illustration focuses on hand positioning and needle insertion technique for injection delivery.*

FDA Label Image

Figure I (Fig I)

An instructional illustration showing a hand holding a syringe and injecting a solution subcutaneously into the skin of an arm. The diagram depicts the injection process for a subcutaneous injection, consistent with the use of Glatiramer Acetate 40 mg/mL injection solution.*

FDA Label Image

Figure J (Fig J)

An instructional illustration showing a hand holding a syringe administering an injection subcutaneously into the skin. The image demonstrates the correct angle and method for subcutaneous injection.*

FDA Label Image

Figure K (Fig K)

Illustration depicting a person preparing to self-inject a subcutaneous injection into their thigh, showing hand positioning and needle angle. This instructional image relates to the proper administration technique for injectable medications like Glatiramer Acetate 40 mg/mL solution.*

FDA Label Image

Figure L (Fig L.png)

An outline illustration showing a sharps disposal container with a lid, typically used for safely discarding needles and syringes. The container has a rectangular base and a slanted top with a flap or slot for depositing used injection items. The background is plain with a gray upper section and white lower section.*

FDA Label Image

Blister Label (Blister Packs 40mg)

Label for Glatiramer Acetate Injection 40 mg/mL, a subcutaneous injection solution. The label indicates administration three times a week and is distributed by Ajenat Pharmaceuticals LLC. Storage conditions specify refrigeration between 36°F to 46°F (2°C to 8°C) and protection from light. The label includes an NDC barcode and states the product is made in China.*

FDA Label Image

Carton Label (Carton 40mg 260205)

Packaging label for Glatiramer Acetate Injection 40 mg/mL by Ajenat Pharmaceuticals LLC. This human prescription drug is a subcutaneous injection, available in a carton containing 12 single-dose pre-filled syringes. The label states dosing as three times a week and includes storage instructions and medication guide information.*

FDA Label Image

Figure 1 (Fig 1)

A Kaplan-Meier curve chart comparing the percentage of second exacerbation over time (up to 1080 days) between Glatiramer Acetate 20 mg and placebo groups. The y-axis represents second exacerbation percentage, and the x-axis shows study days with corresponding subject counts. The Glatiramer Acetate group exhibits a lower cumulative exacerbation rate than placebo. Statistical values indicating p=0.0005 and hazard ratio=0.55 are noted.*

FDA Label Image

Figure 2 (Fig 2)

A line graph comparing the cumulative number of enhancing lesions per brain over a 9-month period for Glatiramer Acetate versus a placebo. The x-axis represents time in months, and the y-axis indicates the cumulative lesion count. The graph shows two lines, one for Glatiramer Acetate and one for placebo, illustrating lesion progression over time.*

FDA Label Image

Figure A (Fig A)

An injection preparation illustration showing a sharps disposal container, syringe in blister package, cotton balls, alcohol wipes, and an injection diary, likely for subcutaneous administration. The image depicts supplies commonly used for self-injection procedures.*

FDA Label Image

Syringe Label (Label For 40mg 260119)

Label for Glatiramer Acetate Injection 40 mg/mL, a subcutaneous injection solution. The label includes the NDC number 82983-430, highlights the product strength with green background, and states 'Rx Only'. Distributed by Ajenat Pharmaceuticals, LLC, the label also features a barcode and space for lot and expiration dates.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.